Clinical Trials Logo
  1. Home
  2. Allergic Rhinitis
  3. NCT05908721
  4. Details
NCT05908721 Clinical Trial

Study of CM310 in Patients With Allergic Rhinitis

Allergic Rhinitis Clinical Trial

Official title:
A Multicenter, Single Arm Phase II Clinical Study Evaluating the Safety of CM310 Recombinant Humanized Monoclonal Antibody Injection in Patients With Seasonal Allergic Rhinitis

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT05908721
Other study ID # CM310-107107
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date October 30, 2023
Est. completion date October 30, 2024

Study information
Verified date June 2023
Source Keymed Biosciences Co.Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a multicenter, single arm, open-label phase II clinical study mainly evaluating the safety of CM310 in patients with allergic rhinitis.

Description:

Allergic rhinitis (AR) is a non infectious chronic inflammatory disease of the nasal mucosa that is mainly mediated by immunoglobulin E (IgE) in atopic individuals exposed to allergens.

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 100
Est. completion date October 30, 2024
Est. primary completion date October 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Male or female aged 18-65. - Understand the study and sign the Informed Consent Form voluntarily. - Take effective contraception measures throughout the study period. Exclusion Criteria: - Used other investigational drugs. - Allergies to drugs with IL-4Ra monoclonal antibody or drug components of CM310. - Plan to participate in other studies during this clinical trial. - With malignant or benign tumors of the nasal cavity. - Other reasons the researcher believes that the subject is not suitable to participate in this study.

Study Design

Related Conditions & MeSH terms

Intervention

Biological:
• CM310
IL-4Ra monoclonal antibody

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Keymed Biosciences Co.Ltd

Outcome
Type Measure Description Time frame Safety issue
Primary Incidence of adverse events Incidence (including number of patients, events and percentage) of adverse events. Week 12
See also
  Status Clinical Trial Phase
Recruiting NCT05080322 - Efficacy and Safety of On-demand and Continuous Administration of Nasal Spray in the Treatment of Allergic Rhinitis Phase 4
Recruiting NCT06028490 - A Study of IL4Rα Monoclonal Antibody in Patients With Uncontrolled Seasonal Allergic Rhinitis. Phase 2
Completed NCT04388358 - Traditional Chinese Medicine for the Treatment of Perennial Allergic Rhinitis on Gut Microbiota and Immune-modulation N/A
Recruiting NCT04202263 - Assessment of Suppression of Cutaneous Allergic Responses and Pruritis by Topical Minocycline Phase 2
Completed NCT04078009 - Standardising Nasal Allergen Challenge in Adult With Hay Fever N/A
Completed NCT03644680 - Changes in Adaptive Immune Responses and Effector Cell Responses Upon Nasal Allergen Exposure - a Pilot Study N/A
Completed NCT04541004 - Adolescent Mite Allergy Safety Evaluation Phase 3
Recruiting NCT05378594 - HDM and Silver Birch NAC Standardisation N/A
Not yet recruiting NCT05684380 - Efficacy and Safety of MAZ-101 in the Treatment of Persistent Allergic Rhinitis (PER) Phase 3
Not yet recruiting NCT01014325 - Safety and Efficacy Study With Allergen Extracts of House Dust Mites for Specific Sublingual Immunotherapy Phase 3
Completed NCT02943720 - ATIBAR - Efficacy and Safety of Two Doses of AllerT in Patients Allergic to Birch Pollen Phase 2
Completed NCT02910401 - Clinical Response to Rhinovirus Challenge Phase 2
Completed NCT02556801 - Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy Phase 2
Completed NCT02352168 - Airway Inflammation in Children With Allergic Rhinitis and Intervention N/A
Not yet recruiting NCT02233426 - Effect of Hypertonic Solutions on Allergic Rhinitis Patients N/A
Completed NCT01946035 - Alpha-Blockers in Allergic Rhinitis (MAN 01) Phase 4
Completed NCT01918956 - PURETHAL Birch RUSH Study Phase 4
Completed NCT01682070 - SUBLIVAC FIX Phleum Pratense DT/DRF Phase 2
Recruiting NCT01454492 - The Relationship Between Allergic Rhinitis and Geographic Tongue N/A
Completed NCT01438463 - PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis Phase 2